Real‐life experience of a lidocaine/tetracaine self‐occluding topical anesthetic for dermatological procedures

2021 ◽  
Author(s):  
Juan Jimenez‐Cauhe ◽  
Pablo Boixeda ◽  
Paloma Cornejo ◽  
Sergio Fernandez ◽  
Maria Vitale ◽  
...  
Keyword(s):  
Life Experience ◽  
Real Life ◽  
Topical Anesthetic

Use of nintedanib for the treatment of idiopathic pulmonary fibrosis: multi-centre real life experience in Germany

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
F Bonella ◽  
M Kreuter ◽  
L Hagmeyer ◽  
C Neurohr ◽  
K Milger ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Life Experience ◽  
Real Life

Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience

2020 ◽  
Vol 19 (10) ◽  
pp. 978-983
Author(s):  
Janina Hahn ◽  
Susanne Trainotti ◽  
Marlene Wigand ◽  
Patrick Schuler ◽  
Thomas Hoffmann ◽  
...  
Keyword(s):  
Life Experience ◽  
Real Life ◽  
Prospective Analysis

Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease

2020 ◽  
Vol 22 (1) ◽  
pp. 32-45
Author(s):  
Emanuela Martina ◽  
Federico Diotallevi ◽  
Tommaso Bianchelli ◽  
Matteo Paolinelli ◽  
Annamaria Offidani
Keyword(s):  
English Language ◽  
Life Experience ◽  
Case Reports ◽  
Immunosuppressive Agents ◽  
Real Life ◽  
Chronic Spontaneous Urticaria ◽  
New Targets ◽  
Current State ◽  
Pubmed Database ◽  
Novel Drugs

Background: Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. For many years the treatment of CSU has been based on the use of antihistamines, steroids and immunosuppressive agents with inconstant and frustrating results. The introduction of omalizumab, the only licensed biologic for antihistamine- refractory CSU, has changed the management of the disease. Objective: The aim of this article is to review the current state of the art of CSU, the real-life experience with omalizumab and the promising drugs that are under development. Methods:: An electronic search was performed to identify studies, case reports, guidelines and reviews focused on the new targets for the treatment of chronic spontaneous urticaria, both approved or under investigation. The search was limited to articles published in peer-reviewed journals in the English Language in the PubMed database and trials registered in Clinicaltrials.gov. Results:: Since the advent of omalizumab, the search for new therapies for chronic spontaneous urticaria has had a new impulse. Anti-IgE drugs will probably still be the cornerstone of therapy, but new targets may prove effective in syndromic urticaria or refractory cases. Conclusion:: Although omalizumab has been a breakthrough in the treatment of CSU, many patients do not completely get benefit and even require more effective treatments. Novel drugs are under investigation with promising results.

scholarly journals Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma

2019 ◽  
Vol 29 (6) ◽  
pp. 648-654 ◽  
Author(s):  
Joanna Mangana ◽  
Florentia Dimitriou ◽  
Ralph Braun ◽  
Sabine Ludwig ◽  
Reinhard Dummer ◽  
...  
Keyword(s):  
Low Dose ◽  
Life Experience ◽  
Real Life ◽  
Stage Iii ◽  
Adjuvant Setting ◽  
Single Center ◽  
Stage Iii Melanoma
Sign in / Sign up

Export Citation Format

Share Document